Miguel Martín, MD, PhD, on Metastatic Breast Cancer: PEARL Trial on Palbociclib Plus Endocrine Therapy vs Capecitabine
2019 San Antonio Breast Cancer Symposium
Miguel Martín, MD, PhD, of the Gregorio Marañón Institute and GEICAM, discusses phase III study findings that showed no improvement in progression-free survival with palbociclib plus endocrine therapy vs capecitabine in patients with hormone receptor–positive/HER2-negative metastatic breast cancer whose disease progressed on aromatase inhibitors—although the drug combination was generally better tolerated than capecitabine (Abstract GS2-07).
Rashmi K. Murthy, MD, of The University of Texas MD Anderson Cancer Center, discusses data on the efficacy and safety of tucatinib, trastuzumab, and capecitabine, a treatment regimen under investigation for patients with advanced HER2-positive metastatic breast cancer refractory to standard-of-care regimens (Abstract GS1-01).
Sara M. Tolaney, MD, MPH, of Dana-Farber Cancer Institute, discusses phase II findings on patients receiving T-DM1 monotherapy as adjuvant treatment for stage I HER2-positive breast cancer, a regimen associated with few recurrences in the study population (Abstract GS1-05).
Joseph Sparano, MD, of the Montefiore Medical Center, discusses three challenges:
- How can gene-expression profiles and other diagnostic tests be used to guide the use of adjuvant systemic therapy?
- Is it time to reappraise active surveillance?
- Are there diagnostic and therapeutic strategies that can identify tumors at highest risk of metastasis, and novel therapies that can block the spread of disease?
Priyanka Sharma, MD, of the University of Kansas Medical Center, reviews new phase III data on adding oral fluoropyrimidine to adjuvant endocrine therapy, the current standard of care, in the setting of hormone receptor–positive, HER2-negative primary breast cancer (Abstract GS1-09).
Ralph R. Weichselbaum, MD, of the University of Chicago, summarizes a plenary lecture in which he presented data that could guide future clinical strategies: studies supporting the basis and classification of oligometastatic disease, including breast cancer; and basic and clinical data on radioimmunotherapy (Abstract PL2).
